The c-MYC-AP4-p21 cascade

Cell Cycle

Volumn 8, Issue 7, 2009, Pages 982-989

  Jung, Peter ^a   Hermeking, Heiko ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AP4; c MYC; Cell cycle; Colorectal cancer; DNA damage; p21; p53; TFAP4; Wnt signaling

Indexed keywords

MYC PROTEIN; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; BREAST CARCINOMA; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; COLON MUCOSA; COLORECTAL CANCER; DNA DAMAGE; DOWN REGULATION; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; UPREGULATION;

EID: 65949100126     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.7.7949     Document Type: Review

References (106)

1. Cole MD, Henriksson M. 25 years of the c-Myc oncogene. Semin Cancer Biol 2006; 16:241. (Pubitemid 44311042)
2. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755-2766
3. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8:976-990
4. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-776 (Pubitemid 37328911)
5. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6:913-924
6. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-3016 (Pubitemid 29276540)
7. Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Annu Rev Biochem 1992; 61:809-860
8. Chappell SA, LeQuesne JP, Paulin FE, deSchoolmeester ML, Stoneley M, Soutar RL, et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene 2000; 19:4437-4440
9. Albert T, Urlbauer B, Kohlhuber F, Hammersen B, Eick D. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 1994; 9:759-763 (Pubitemid 24065913)
10. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18:717-726 (Pubitemid 29057256)
11. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981; 290:475-480 (Pubitemid 11159077)
12. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103:18261-18266
13. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-1512
14. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:241-250
15. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation and migration. Genes Dev 2004; 18:1385-1390
16. Clevers H. Axin and hepatocellular carcinomas. Nat Genet 2000; 24:206-208 (Pubitemid 30132183)
17. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1 and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21:4863-4871
18. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-1851. (Pubitemid 30639518)
19. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006; 25:3479-3488
20. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol 2007; 27:5135-5146 (Pubitemid 47068288)
21. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14:447-457
22. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994; 265:2091-2093 (Pubitemid 24325691)
23. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002; 9:1031-1044 (Pubitemid 34626672)
24. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Nontranscriptional control of DNA replication by c-Myc. Nature 2007; 448:445-451
25. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207. (Pubitemid 29456888)
26. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 2006; 281:14446-14456 (Pubitemid 43848375)
27. Menssen A, Epanchintsev A, Lodygin D, Rezaei N, Jung P, Verdoodt B, et al. c-MYC Delays Prometaphase by Direct Transactivation of MAD2 and BubR1: Identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 2007; 6:339-352
28. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 2006; 16:242-252 (Pubitemid 44311041)
29. Cowling VH, Cole MD. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol 2007; 27:2059-2073 (Pubitemid 46418464)
30. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6:635-645 (Pubitemid 41081267)
31. Ayer DE, Eisenman RN. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 1993; 7:2110-2119 (Pubitemid 23336138)
32. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995; 80:767-776
33. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003; 283:17-21. (Pubitemid 36259892)
34. Smale ST, Baltimore D. The "initiator" as a transcription control element. Cell 1989; 57:103-113
35. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 1994; 13:4070-4079 (Pubitemid 24275863)
36. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001; 20:1688-1702
37. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. EMBO J 1997; 16:5672-5686 (Pubitemid 27399859)
38. Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. Science 1993; 262:1889-1892. (Pubitemid 124000643)
39. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98:4510-4515
40. Roy AL, Carruthers C, Gutjahr T, Roeder RG. Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 1993; 365:359-361 (Pubitemid 23288980)
41. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, Funa K. Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J Cell Sci 2001; 114:1533-1544 (Pubitemid 32427839)
42. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3:392-399
43. Jung P, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci USA 2008; 105:15046-15051
44. Mermod N, Williams TJ, Tjian R. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988; 332:557-561 (Pubitemid 18107927)
45. Hu YF, Luscher B, Admon A, Mermod N, Tjian R. Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev 1990; 4:1741-1752 (Pubitemid 20352073)
46. Atchley WR, Fitch WM. A natural classification of the basic helix-loop-helix class of transcription factors. Proc Natl Acad Sci USA 1997; 94:5172-5176 (Pubitemid 27214756)
47. Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem 2005; 280:27638-27644 (Pubitemid 41076876)
48. Kim MY, Jeong BC, Lee JH, Kee HJ, Kook H, Kim NS, et al. A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells. Proc Natl Acad Sci USA 2006; 103:13074-13079
49. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-12505 (Pubitemid 43855336)
50. Cui Y, Narayanan CS, Zhou J, Kumar A. Exon-I is involved in positive as well as negative regulation of human angiotensinogen gene expression. Gene 1998; 224:97-107. (Pubitemid 29023545)
51. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999; 18:2916-2924 (Pubitemid 29276532)
52. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23:1686-1690
53. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90:7804-7808 (Pubitemid 23250039)
54. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci USA 2003; 100:5313-5318 (Pubitemid 36542702)
55. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 2006; 103:17834-17839
56. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 2007; 106:461-468 (Pubitemid 47302473)
57. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992; 7:1587-1594
58. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 2005; 25:7917-7925 (Pubitemid 41170149)
59. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002; 10:509-521
60. CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003; 22:351-360
61. Adhikary S, Peukert K, Karsunky H, Beuger V, Lutz W, Elsasser HP, et al. Miz1 is required for early embryonic development during gastrulation. Mol Cell Biol 2003; 23:7648-7657
62. Ziegelbauer J, Wei J, Tjian R. Myc-interacting protein 1 target gene profile: a link to microtubules, extracellular signal-regulated kinase, and cell growth. Proc Natl Acad Sci USA 2004; 101:458-463 (Pubitemid 38084658)
63. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6:1054-1060 (Pubitemid 41486191)
64. CIP1 and controls the cellular response to p53 activation. EMBO J 2008; 27:1563-1574
65. Brenner C, Deplus R, Didelot C, Loriot A, Vire E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 2005; 24:336-346
66. Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol 1997; 17:5888-5896 (Pubitemid 27411095)
67. Liu Y, Encinas M, Comella JX, Aldea M, Gallego C. Basic helix-loop-helix proteins bind to TrkB and p21(Cip1) promoters linking differentiation and cell cycle arrest in neuroblastoma cells. Mol Cell Biol 2004; 24:2662-2672 (Pubitemid 38381259)
68. CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell cycle arrest. Proc Natl Acad Sci USA 2000; 97:9498-9503
69. Ou SH, Garcia-Martinez LF, Paulssen EJ, Gaynor RB. Role of flanking E box motifs in human immunodeficiency virus type 1 TATA element function. J Virol 1994; 68:7188-7199 (Pubitemid 24328771)
70. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004; 3:1133-1137 (Pubitemid 40268631)
71. Cip1 gene. Genes Dev 2006; 20:2024-2029
72. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118:3943-3953
73. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62:3126-3131 (Pubitemid 34602404)
74. WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005; 280:17617-17625
75. Venditti M, Iwasiow B, Orr FW, Shiu RP. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002; 99:35-42. (Pubitemid 34273195)
76. Bierie B, Moses HL. TGFbeta and cancer. Cytokine Growth Factor Rev 2006; 17:29-40.
77. Coffey RJ Jr, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol 1988; 8:3088-3093 (Pubitemid 18192487)
78. Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002; 110:19-32.
79. Hannon GJ, Beach D. p15INK4B is a potential effector of TGFbeta-induced cell cycle arrest. Nature 1994; 371:257-261 (Pubitemid 2126463)
80. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92:5545-5549
81. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cell cycle arrest by cytokine TGFbeta in cells lacking the CDK inhibitor p15. Nature 1997; 387:417-422 (Pubitemid 27227208)
82. Pardali K, Kowanetz M, Heldin CH, Moustakas A. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 2005; 204:260-272 (Pubitemid 40776829)
83. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-821 (Pubitemid 37376979)
84. van den Brink GR, Offerhaus GJ. The morphogenetic code and colon cancer development. Cancer Cell 2007; 11:109-117 (Pubitemid 46209852)
85. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer and heritable disorders. Cell 2000; 103:295-309.
86. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E, et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol 2006; 26:8418-8426
87. van den Brink GR, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, Keller JJ, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 2004; 36:277-282
88. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996; 179:248-253 (Pubitemid 26266401)
89. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446:676-679
90. Cao J, Tang M, Li WL, Du H, Tang WB, Wang H, et al. Upregulation of activator protein-4 in human colorectal cancer with metastasis. Int J Surg Pathol 2008; 17:16-21.
91. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, et al. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60:1180-1199
92. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297:102-104
93. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109:321-334 (Pubitemid 34606875)
94. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431:1112-1117
95. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679-683
96. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. Chem Med Chem 2007; 2:627-630
97. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007; 6:2399-2408
98. 1 cyclin-cdk complexes. EMBO J 1995; 14:4814-4826
99. WAF1/CIP1/SDI1. Oncogene 1995; 11:1409-1415
100. Kip1 is abrogated by c-Myc. EMBO J 1996; 15:6595-6604
101. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors overexpressing MYC. Nat Med 2007; 13:820-827 (Pubitemid 47038193)
102. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419:729-734 (Pubitemid 35177959)
103. Lo PK, Huang SZ, Chen HC, Wang FF. The prosurvival activity of p53 protects cells from UV-induced apoptosis by inhibiting c-Jun NH2-terminal kinase activity and mitochondrial death signaling. Cancer Res 2004; 64:8736-8745 (Pubitemid 39552091)
104. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105:533-539 (Pubitemid 30127254)
105. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501
106. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3:1034-1036